Images List Premium Download Classic

Anxiety

Anxiety-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity
Auspex Pharmaceuticals, Inc.
March 29, 2018 - N°20180085327

Chemical syntheses and medical uses of novel inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts and prodrugs thereof, for the treatment and/or management of psychotropic disorders, anxiety disorder, generalized anxiety disorder, depression, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, hot flashes, senile dementia, migraine, hepatopulmonary syndrome, chronic pain, nociceptive pain, neuropathic pain, painful diabetic retinopathy, bipolar ...
Gabaergic ligands and their uses
Uwm Research Foundation, Inc.
March 08, 2018 - N°20180065967

Described herein are α3 or α2 or α2/α3 gabaergic receptor subtype selective ligands, pharmaceutical compositions, and methods of use of such ligands and compositions in treatment of anxiety disorders, epilepsy and schizophrenia with reduced sedative and ataxic side effects. In embodiments, such as α3 or α2 or α2/α3 gabaergic receptor ...
Compositions of medicinal plants for reducing the effects of aging, prevention and treatment of age-related ...
Pharmacogenetics Limited
March 08, 2018 - N°20180064773

Compositions comprising extracts prepared from mixtures of the herbal plants radix bupleurum chinense dc (“b”), rhizoma corydalis yanhusuo wt wang (“y”), caulis polygonum multiflorum thunb (“p”) and flos albizia julibrissin durazz (“a”) are provided. The byp, bya, bpa, by, bp, yp and bypa extracts ...
Anxiety Patent Pack
Download + patent application PDFs
Anxiety Patent Applications
Download + Anxiety-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Anxiety-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Salts, co-crystals, and polymorphs of an anxiolytic compound
Ironwood Pharmaceuticals, Inc.
December 21, 2017 - N°20170362230

The present invention provides crystalline forms fum-p3, fum-p4, mla-p3 and mla-p4 of compound formula 1 and related methods of treating and/or preventing a disease, such as a central nervous system disease (e. G., an anxiety disorder), using a crystalline form fum-p3, fum-p4, mla-p3 and mla-p4 of compound formula 1 and/or pharmaceutical compositions thereof.
Glutamate agents in the treatment of mental disorders
Yale University
December 21, 2017 - N°20170360775

Methods of treating mental disorders, including anxiety disorders such as obsessive-compulsive disorder, are provided. The methods comprise administering an effective amount of a glutamate modulator to an individual in need thereof. Also provided are methods of enhancing the activity of a serotonin reuptake inhibitor (sri) comprising co-administering a glutamate modulator and a serotonin reuptake inhibitor. Pharmaceutical composition comprising a serotonin ...
Neuroactive steroids, compositions, and uses thereof
Sage Therapeutics, Inc.
December 07, 2017 - N°20170348327

Described herein are methods of treating tremor, e. G., essential tremor; depression, e. G., postpostum depression; and anxiety disorder, the method comprising administering to a human subject suffering from tremor, e. G., essential tremor; depression, e. G., postpostum depression, an anxiety disorder with a neuroactive steroid or a composition comprising a neuroactive steroid (e. G., pregnanolone, allopregnanolone, alphadalone, ganaxolone, or ...
Anxiety Patent Pack
Download + patent application PDFs
Anxiety Patent Applications
Download + Anxiety-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Anxiety-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Anti-acth antibodies and use thereof
Alder Biopharmaceuticals, Inc.
November 23, 2017 - N°20170334987

The present invention is directed to antibodies and fragments thereof having binding specificity for acth. Another embodiment of this invention relates to the antibodies binding fragments thereof described herein, comprising the sequences of the vh, vl and/or cdr polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-acth antibodies and binding fragments thereof conjugated ...
Xenon and/or argon treatment as an adjunct to psychotherapy for psychiatric disorders
November 02, 2017 - N°20170312308

The present invention relates generally to the fields of treating psychiatric disorders, in particular, anxiety disorders including post-traumatic stress disorder (ptsd) in subjects, e. G., human subjects, by administering a xenon and/or argon containing composition. Treatments can also employ psychotherapy in combination with administration of xenon and/or argon, alone or in combination with additional psychotherapeutic medications to treat ...
Antagonists of the kappa opioid receptor
University Of Kansas
September 14, 2017 - N°20170260141

The present technology is directed to compounds, compositions, and methods related to non-morphinan-like kappa opioid receptor (kor) antagonists. The technology is suited to treat addiction, diuresis, depression, post traumatic stress disorder, an eating disorder, panic disorder, social anxiety disorder, general anxiety disorder, obsessive compulsive disorders, excessive or unreasonable specific phobias, and/or other conditions related to anxiety or aversion-reward responses.
Method of enhancing a participant's performance in a sporting activity
September 14, 2017 - N°20170259149

According to one aspect of the present invention, a method of improving a participant's ability to move an object toward a desired target through athletic movement is provided. The method comprises establishing a point of focus that is positioned outward from a participant's body. The method further comprises instructing the participant to continuously move the point of focus through one ...
Disease susceptibility
Leiden University
August 24, 2017 - N°20170240967

The invention provides a method of assessing the susceptibility of a subject to, or aiding the diagnosis of, an anxiety disorder or depression, the method comprising determining whether the subject has a haplotype comprising rs3216799, rs6814934, rs7658048, rs2070950 and rs2070951 with respective alleles ‘+ct, ‘c’, ‘t’, ‘c’ and ‘c’. The invention ...
Process for the synthesis of (+) and (-)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane
Euthymics Bioscience, Inc.
August 17, 2017 - N°20170233333

The present invention is concerned with novel processes for the preparation of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3. 1. 0]hexane or a pharmaceutically acceptable salt thereof, and (−)-1-(3,4-dichlorophenyl)-3-azabicyclo[3. 1. 0]hexane or a pharmaceutically acceptable salt thereof. These compounds have pharmaceutical utility and are known to be useful for treating e. G., depression, anxiety disorders, eating disorders and urinary ...
Nutritional supplement for use in combatting stress and anxiety in pets
Domes Pharma
July 27, 2017 - N°20170209547

Nutritional supplement for veterinary, for use in combatting stress and anxiety in pets, characterized in that it contains a mixture of α-lactalbumin and magnesium.
Anxiety Patent Pack
Download + patent application PDFs
Anxiety Patent Applications
Download + Anxiety-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Anxiety-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride
Merck Patentgesellschaft
June 29, 2017 - N°20170182037

The invention relates to new crystalline modifications of the hydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine, crystalline modification of the dihydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and amorphous 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride which are suitable in particular for the preparation of solid ...
Exo-s-mecamylamine formulation and use in treatment
University Of South Florida
June 29, 2017 - N°20170181983

A pharmaceutical composition includes a therapeutically effective amount of exo-s-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-r-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0. 5 mg to about 20 mg. Medical conditions are treated by administering a therapeutically effective amount of exo-s-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of its exo-r-mecamylamine, said ...
Neuroplasticity games for depression
May 25, 2017 - N°20170148343

A training program is configured to systematically drive neurological changes to treat depression, mood and anxiety disorders. The training program includes an inference renormalization game that presents three subsets of stimuli and prompts a game participant to selectively respond or withhold responding to one or two of the stimulus subsets.
Compositions and methods for the treatment of neurological diseases
May 11, 2017 - N°20170129870

The compositions and compounds of formula i which includes a salt of duloxetine or its polymorphs, enantiomers, stereoisomers, solvates, and hydrates thereof. These salts may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of major depressive disorder, ...
System and method for enabling a user to overcome social anxiety
Dharma Life Sciences Llc
May 04, 2017 - N°20170124905

A system is provided for enabling a user to overcome social anxiety. The system is configured to enable the user to engage in a first and a second activity in a virtual environment, directed to rewire a first and a second defective wiring, respectively. The first defective wiring results in an individual give priority to threatening information in social environments. ...
Magnesium compositions and uses thereof for neurological disorders
Neurocentria, Inc.
April 27, 2017 - N°20170112875

A composition for administration to a subject, such as oral administration to a subject, for example, has been provided. Such a composition may comprise at least one magnesium-counter ion compound. A magnesium-counter ion composition described herein may be useful for any of a variety of applications provided herein, such as maintaining, enhancing, and/or improving health, nutrition, and/or another ...
Magnesium compositions and uses thereof for neurological disorders
Neurocentria, Inc.
April 20, 2017 - N°20170106016

A composition for administration to a subject, such as oral administration to a subject, for example, has been provided. Such a composition may comprise at least one magnesium-counter ion compound. A magnesium-counter ion composition described herein may be useful for any of a variety of applications provided herein, such as maintaining, enhancing, and/or improving health, nutrition, and/or another ...
Indolin-2-one or pyrrolo-pyridin-2-one derivatives
April 13, 2017 - N°20170101409

The compounds may be used in the treatment of cns diseases related to positive (psychosis) and negative symptoms of schizophrenia, substance abuse, alcohol and drug addiction, obsessive-compulsive disorders, cognitive impairment, bipolar disorders, mood disorders, major depression, treatment resistant depression, anxiety disorders, alzheimer's disease, autism, parkinson's disease, chronic pain, borderline personality disorder, neurodegenerative disease, sleep disturbances, chronic fatigue syndrome, stiffness, inflammatory ...
Loading